NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Immatics N.V. (IMTX) Stock Analysis

Immatics N.V. (IMTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IMTX

$9.56

+$0.10 (+1.06%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMTX with… →

IMTX Key Statistics

As of Sep 4, 2026
Trading
Open
$9.34
Previous Close
$9.46
Day's Range
9.30–9.57
52-Week Range
5.67–12.41
Volume
497.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.33
Valuation
Market Cap
$1.46B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
34.90
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.86
Financials (FY)
Revenue (FY)
$48.27M−69.03%
Net Income (FY)
−$196.45M−1390.89%
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
152.23M
1-Year Return
+67.13%
Dividend and dates
Earnings Date
November 17, 2026estimated
Avg Volume
465.95K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IMTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−8.95%
2025+47.68%
2024−32.48%
2023+20.90%
2022−35.19%
2021+24.56%
2020+3.75%
2019+6.12%
2018 (partial year)+2.08%

As of September 4, 2026.

IMTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$48.27M−$196.45M−407.0%
2024$155.84M$15.22M9.8%
2023$54.00M−$94.65M−175.3%
2022$172.83M$27.70M16.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$48.27M—−$182.02M−$196.45M−407.0%
2024$155.84M—−$38.62M$15.22M9.8%
2023$54.00M—−$101.73M−$94.65M−175.3%
2022$172.83M—$29.95M$27.70M16.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IMTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricIMTXBiotechnology medianvs median
P/S ratio34.9015.26129% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Immatics N.V. (IMTX) at $1.46B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 704 employees.

IMTX last closed at $9.56 on September 4, 2026. That is +$0.10 (+1.06%) against the previous close. The 52-week range on file runs from $5.67 to $12.41. The latest close sits 68.61% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $48.27M. Against the prior fiscal year total of $155.84M, that is a change of −69.03%. The same year closed with a net loss of $196.45M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −1.86.

Across the 4 fiscal years on file, revenue moves from $172.83M in 2022 to $48.27M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 34.9. On price-to-sales that is 128.62% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.33. Annualized volatility over the trailing 7 years is 55.04%. The trailing one-year price return is +67.13%. Measured over 5 years, that is −6.60% a year compounded.

Growth & Income

No dividend is on file for IMTX.

Across the complete calendar years on file, 2025 returned +47.68% and 2022 returned −35.19%. Of the 7 complete calendar years on file, 5 finished higher. 2026 is still running; the price is −8.95% year to date.

Peer Comparison

Immatics N.V. (IMTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Immatics N.V. IMTX $1.46B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Immatics N.V. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Immatics N.V.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Visit website →